PFS of patients with persistent lymphocytosis is not inferior to those achieving complete or PR by 12 months. This is a landmark analysis at day 365 comparing patients with PR-L at 12 months vs those with CR/PR at 12 months. There is no statistical difference between these groups, although there is a trend toward improved survival in patients with PR-L.